Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Does Nirsevimab Prevent Lower Respiratory Infections Caused by Respiratory Syncytial Virus?
2024
· University of Virginia
This study examines nirsevimab, a monoclonal antibody that helps prevent respiratory syncytial virus (RSV) infections in infants. It found that one injection of nirsevimab significantly …
Ask aRCie
Outpatient Respiratory Syncytial Virus Infections and Novel Preventive Interventions
2024
· University Medical Center Utrecht,
· Respiratory Syncytial Virus NETwork (ReSViNET) Foundation
This article focuses on respiratory syncytial virus (RSV) infections that occur outside of hospitals. It describes new ways to prevent these infections, which are common …
Rapid Review Showed That Real-World Results on How Nirsevimab Prevented Respiratory Syncytial Virus Hospitalisations Were Similar to Randomised Trials
This brief report describes a study on nirsevimab, a treatment to prevent RSV hospitalizations in infants. Real-world results from studies in Luxembourg, Spain, and the …
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows …
Nirsevimab to Reduce Infant Morbidity From Respiratory Syncytial Virus
This article describes how nirsevimab, a long-acting monoclonal antibody, helps prevent respiratory syncytial virus (RSV) infections in infants. RSV is a common virus that can …
Nirsevimab Brings Breakthrough in the Prevention of Respiratory Syncytial Virus Infection in Infants - Importance of Design
2023
· Capital Medical University
This editorial reviews the clinical studies on nirsevimab and discusses what roles the design has played in the studies. Nirsevimab is a monoclonal antibody that …
Nirsevimab-A Breakthrough in Respiratory Syncytial Virus Bronchiolitis
2024
· Paris Cité University,
· McGill University
This article comments on immunization programs with nirsevimab that began in 2023 in some countries like France, with its impact being studied in recent publications. …
Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment
This article provides guidance on preventing respiratory syncytial virus (RSV) in infants. It describes two new FDA-approved options: Beyfortus, a monoclonal antibody for infants, and …
Impact of Nirsevimab on Admission to a Spanish Pediatric Intensive Care Unit Because of RSV Bronchiolitis: Unicentric Observational Study from 2017 to 2024
This letter describes admissions to a pediatric critical care unit (PICU) because of acute bronchiolitis caused by respiratory syncytial virus. The study looked at a …
RSV Prevention Within Reach for Older Infants and Toddlers: The Role of Active Immunization
This article reviews efforts to prevent RSV in older infants and toddlers through active immunization. It highlights the global impact of RSV, especially in young …